JOURNAL OF THE CZECH PEDIATRIC SOCIETY AND THE SLOVAK PEDIATRIC SOCIETY

Čes-slov Pediat 2025, 80(6):286-290 | DOI: 10.55095/CSPediatrie2025/037

Complicated pneumonia in a vaccinated child - caused by Streptococcus pneumoniae serotype 3

Daniel Točík1, Adam Švepeš1, Jan Hřídel1, Sandra Vohrnová2, 3, Jana Kozáková2, Jakub Jonáš4
1 Dětské oddělení, Nemocnice České Budějovice a.s.
2 Národní referenční laboratoř pro streptokokové nákazy, Centrum epidemiologie a mikrobiologie, Státní zdravotní ústav, Praha
3 3. lékařská fakulta, Univerzita Karlova, Praha
4 Klinika anesteziologie, resuscitace a intenzivní medicíny, 2. lékařská fakulta, Univerzita Karlova a Fakultní nemocnice Motol, Praha

Streptococcus pneumoniae remains the leading cause of pneumonia in children under 5 years of age worldwide, despite established vaccination programs. This case report describes a severe course of pneumonia complicated with fluidothorax, lung atelectasis and necrosis of lung parenchyma, requiring surgical intervention. The causative pathogen was identified as Streptococcus pneumoniae, specifically serotype 3, which is included in the pneumococcal conjugate vaccine administered to the patient previously according to the recommended schedule. Serotype 3 in one of the most frequently reported pneumococcal serotypes assosiated with vaccine failure.

Keywords: pneumonia, fluidothorax, Streptococcus pneumoniae, serotype 3, vaccination

Received: July 21, 2025; Revised: July 21, 2025; Accepted: August 22, 2025; Published: August 1, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Točík D, Švepeš A, Hřídel J, Vohrnová S, Kozáková J, Jonáš J. Complicated pneumonia in a vaccinated child - caused by Streptococcus pneumoniae serotype 3. Ces-slov Pediat. 2025;80(6):286-290. doi: 10.55095/CSPediatrie2025/037.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. . WHO. Pneumonia in children. Dostupné na: https://www.who.int/news-room/fact-sheets/detail/pneumonia
    2. . Wahl B, O'Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health 2018; 6(7): e744-e757. Go to original source... Go to PubMed...
    3. . GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 2017; 17(11): 1133-1161. Go to original source... Go to PubMed...
    4. . Doporučení České vakcinologické společnosti ČLS JEP. Dostupné na: https://www.vakcinace.eu/doporuceni-a-stanoviska
    5. . ÚZIS ČR. Aktuální data o proočkovanosti české populace. Dostupné na: https://www.nzip.cz/data/ceo/analyticke-studie/ceo-vakcinace-prehled/ceo-vakcinace-prehled.pdf
    6. . Nelson AL, Roche AM, Gould JM, et al. Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance. Infect Immun 2007; 75(1): 83-90. Go to original source... Go to PubMed...
    7. . Luck JN, Tettelin H, Orihuela CJ. Sugar-coated killer: serotype 3 pneumococcal disease. Front Cell Infect Microbiol 2020; 10: 613287. Go to original source... Go to PubMed...
    8. . Kim JO, Romero-Steiner S, Sørensen UB, et al. Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. Infect Immun 1999; 67(5): 2327-33. Go to original source... Go to PubMed...
    9. . Hyams C, Camberlein E, Cohen JM, et al. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun 2010; 78(2): 704-15. Go to original source... Go to PubMed...
    10. . Hammerschmidt S, Wolff S, Hocke A, et al. Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells. Infect Immun 2005; 73(8): 4653-67. Go to original source... Go to PubMed...
    11. . Choi EH, Zhang F, Lu YJ, et al. Capsular polysaccharide (CPS) release by serotype 3 pneumococcal strains reduces the protective effect of anti-type 3 CPS antibodies. Clin Vaccine Immunol 2015; 23(2): 162-7. Go to original source... Go to PubMed...
    12. . Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014; 14(9): 839-46. Go to original source... Go to PubMed...
    13. . Invazivní pneumokoková onemocnění v České republice. Zprávy Centra epidemiologie a mikrobiologie. Dostupné na: https: //szu.gov.cz/temata-zdravi-a-bezpecnosti/a-z-infekce/s/streptokokova-infekce/invazivni-pneumokokova-onemocneni-v-ceske-republice/
    14. . Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15(3): 301-9. Go to original source... Go to PubMed...
    15. . Savulescu C, Krizova P, Lepoutre A, et al. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children inSpIDnet countries: an observational multicentre study. Lancet Respir Med 2017; 5(8): 648-656. Go to original source... Go to PubMed...
    16. . Slotved HC, Dalby T, Harboe ZB, et al. The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination. Heliyon 2016; 2(11): e00198. Go to original source... Go to PubMed...
    17. . Wijayasri S, Hillier K, Lim GH, et al. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017. PLoS One 2019; 14(12): e0226353. Go to original source... Go to PubMed...
    18. . Ho PL, Law PY, Chiu SS. Increase in incidence of invasive pneumococcal disease caused by serotype 3 in children eight years after the introduction of the pneumococcal conjugate vaccine in Hong Kong. Hum Vaccin Immunother 2019; 15(2): 455-458. Go to original source... Go to PubMed...
    19. . Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis 2018; 18(4): 441-451. Go to original source... Go to PubMed...
    20. . Goettler D, Streng A, Kemmling D, et al. Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany. Vaccine 2020; 38(3): 570-577. Go to original source... Go to PubMed...
    21. . Mungall BA, Hoet B, Nieto Guevara J, et al. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Rev Vaccines 2022; 21(2): 201-214. Go to original source... Go to PubMed...
    22. . Ricketson LJ, Bettinger JA, Sadarangani M, et al. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study. Vaccine 2022; 40(19): 2733-2740. Go to original source... Go to PubMed...
    23. . Feemster K, Weaver J, Buchwald U, et al. Pneumococcal vaccine breakthrough and failure in infants and children: a narrative review. Vaccines (Basel) 2023; 11(12): 1750. Go to original source... Go to PubMed...
    24. . Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013; 57(7): 952-62. Go to original source... Go to PubMed...
    25. . Lupinacci R, Rupp R, Wittawatmongkol O, et al. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine 2023; 41(5): 1142-1152. Go to original source... Go to PubMed...
    26. . Wagner G, Gartlehner G, Thaler K, et al. Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis. npj Vaccines 2024; 9: 257. Go to original source... Go to PubMed...
    27. . Heinige P, Slováková L, Vočková J, et al. Impact of the COVID-19 pandemic on pediatric pneumonia outcomes: a five-year retrospective cohort study. Infect Drug Resist 2025; 18: 3511-3525. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content